Trial reportPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2025
Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.
Trial report in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sex assigned at birth may modify health-related quality of life in children treated with peanut oral immunotherapy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2025Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe high burden of peanut allergy underscores the need for treatment options that improve patient health-related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment-related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT-003 trial.
methodsPPOIT-003 was a multicenter, randomized controlled trial in 201 children with peanut allergy (aged 1-10) allocated to combined probiotic and peanut oral immunotherapy (PPOIT), peanut oral immunotherapy alone (OIT), or placebo. Participant HRQL was measured with the Food Allergy Quality of Life-Parent Form (FAQLQ-PF) at baseline, end-of-treatment, and 12 months post-treatment. Multivariable linear regression with an interaction term was used to investigate the relationship between treatment and HRQL in males (N = 128, 63.68%) and females (N = 73, 36.32%).
resultsSex-modification of total FAQLQ-PF scores was present between baseline to end of 12 month follow-up (p = .008). In this time, improvement in FAQLQ-PF scores was significantly better in active compared to placebo groups for males (PPOIT vs. Placebo: -1.003 [95% CI: -1.571, -0.436]; OIT vs. Placebo: -1.250 [95% CI: -1.805, -0.695]), but not for females where improvement also occurred in the placebo group (PPOIT vs. Placebo: -0.148 [95% CI: -0.914, 0.617]; OIT vs. Placebo: 0.252 [95% CI: -0.547, 1.052]). Separate analysis of study phases revealed sex effect modification was greater during treatment than during post-treatment follow-up in domains related to food anxiety (p = .037) and emotional impact of allergy (p = .063).
conclusionSex modifies HRQL outcomes during peanut OIT. Greater understanding of the biological and psychosocial drivers of post-treatment HRQL will facilitate personalized management approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.